Avacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update
05 Abril 2024 - 2:30PM
UK Regulatory
Avacta Group - AVA6000 Abstract Release by AACR and Full
Presentation Update
5
April 2024
Avacta Group plc
(“Avacta” or “the Group” or “the Company”)
AVA6000 Abstract Release by AACR and Full
Presentation Update
Avacta Group plc (AIM: AVCT), a life sciences
company developing innovative, targeted oncology drugs and powerful
diagnostics, today announces that the abstract of the poster to be
presented at the American Association of Cancer Research (“AACR”)
Annual Meeting in San Diego, California on Tuesday 9 April has now
been released by AACR.
The poster presentation will be based on data
from the Phase 1a trial of AVA6000, a peptide drug conjugate
consisting of doxorubicin conjugated with a peptide moiety that is
specifically cleaved by fibroblast activation protein (FAP) in the
tumor microenvironment.
Christina Coughlin, MD, PhD, Head of Research
& Development and Simon Bennett, DPhil, Chief Business Officer,
will be attending the conference with colleagues.
Presentation details
Title: A Phase 1 trial of AVA6000, a Fibroblast
Activation Protein (FAP)-released and tumor microenvironment
(TME)-targeted doxorubicin peptide drug conjugate in patients with
FAP-positive solid tumors
Session Title: First-in-Human Phase 1 Clinical
Trials 2
Session Date and Time: Tuesday 9 April 2024
9:00 AM - 12:30 PM (PDT)
Location: San Diego Convention Center, San
Diego CA USA
Abstract Presentation Number: CT188
First Author: Udai Banerji, MD, PhD, The
Institute of Cancer Research, London, and The Royal Marsden NHS
Foundation Trust
The presentation will include updated data from
the Phase 1 trial beyond those included in the abstract. A copy of
the abstract will be available on Avacta’s website at:
https://avacta.com/about/scientific-resources/.
Copies of the poster will be available on
Avacta's website following the conference at:
https://avacta.com/about/resources/posters/.
Christina Coughlin will provide a video presentation overview
examining the data presented in the poster. This will be available
on 10th April at
https://avacta.com/investors/documents-presentations/.
Alastair Smith, Avacta Chief Executive Officer,
will also be hosting a webinar on Wednesday, April 10 2024 at
5.30pm BST to discuss the data. Registration for the event is via
the following link:
https://www.turnerpope.com/register/
-Ends-
For further information from Avacta
Group plc, please contact:
Avacta Group
plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Michael Vinegrad, Group Communications Director
|
Tel: +44 (0) 1904 21 7070
www.avacta.com |
|
|
Stifel Nicolaus Europe
Limited (Nomad and Joint Broker)
Nicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Ben
Good
|
Tel: +44 (0) 207 710 7600
www.stifel.com |
Peel Hunt (Joint Broker)
James Steel / Chris Golden / Patrick Birkholm |
Tel: +44 (0) 207 418 8900
www.peelhunt.com
|
ICR Consilium (Media and IR)
Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji |
avacta@consilium-comms.com |
About AVA6000
AVA6000, Avacta Therapeutics’ lead oncology program, is a peptide
drug conjugate consisting of doxorubicin conjugated with a peptide
moiety that is specifically cleaved by fibroblast activation
protein (FAP) in the tumor microenvironment (TME). FAP is
selectively overexpressed in many solid tumors. The peptide moiety
(pre|CISIONTM) prevents cellular entry of doxorubicin
unless cleaved by FAP, thus enabling targeted delivery of
doxorubicin directly to the TME.
About Avacta Group plc -
https://www.avacta.com
Avacta Group is a UK-based company focused on improving healthcare
outcomes through targeted cancer treatments and diagnostics.
Avacta has two divisions: an oncology biotech
division harnessing proprietary therapeutic platforms to develop
novel, highly targeted cancer drugs, and a diagnostics division,
which is executing on an M&A led growth strategy to create a
full-spectrum diagnostics business focused on supporting healthcare
professionals and broadening access to testing. Avacta’s two
proprietary platforms, Affimer® and pre|CISION™ underpin its cancer
therapeutics whilst the diagnostics division leverages the Affimer®
platform to drive competitive advantage in its markets.
The pre|CISION™ platform modifies chemotherapy
to be activated only in the tumour tissue, reducing systemic
exposure and toxicity. This is achieved by harnessing an enzyme
called FAP which is highly upregulated in most solid tumours
compared with healthy tissues, turning chemotherapy into a
“precision medicine”. The lead pre|CISION™ programme, AVA6000 a
tumour activated form of doxorubicin, is in Phase 1 studies and has
shown dramatic improvement in safety compared with standard
doxorubicin, and early signs of clinical activity.
To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
Avacta (LSE:AVCT)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Avacta (LSE:AVCT)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024